HONG KONG, Oct. 10, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase III clinical study (COMPASSION-40/AK104-313) evaluating cadonilimab, its first-in-class PD-1/CTLA-4 bispecific antibody, as monotherapy in the neoadjuvant/adjuvant (perioperative) treatment of resectable microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colon cancer.

This marks a significant new indication for cadonilimab beyond gastric, lung, and cervical cancers, and represents the 13th Phase III/registrational study of the therapy conducted globally. Cadonilimab has moved from later-line to first-line treatment of advanced disease and is now being evaluated in the perioperative setting, further broadening its clinical footprint in immuno-oncology (IO) 2.0.

Colorectal cancer is among the malignancies with the highest incidence and mortality worldwide, with colon cancer accounting for most cases. Perioperative outcomes are a major determinant of long-term prognosis. Patients with MSI-H/dMMR colon cancer derive limited benefit from conventional perioperative chemotherapy, with pathological response rates of only approximately 7%—a persistent and significant unmet medical need.

In metastatic MSI-H/dMMR colorectal cancer, immune checkpoint inhibitors are already established as the standard of care. In localized disease, perioperative treatment holds the potential for curative intent and the prospect of durable clinical cure—an area of substantial clinical importance and patient value. While multiple exploratory studies of PD-(L)1 monoclonal antibodies in this setting have shown encouraging efficacy signals, no immunotherapy has yet been approved anywhere for the perioperative treatment of localized MSI-H/dMMR colon cancer.

MSI-H/dMMR colon cancer is highly responsive to immunotherapy due to its high tumor mutational burden and inflamed immune microenvironment. However, single-target immune checkpoint inhibitors still leave room for improved outcomes. By dual blockade of the PD-1 and CTLA-4 pathways, cadonilimab is designed to more effectively activate and sustain antitumor immune responses in the perioperative setting. This approach has the potential to increase rates of major pathological response (MPR) and pathological complete response (pCR), thereby lowering the risk of postoperative recurrence and improving long-term survival.

Supporting evidence comes from a prior Phase II study of cadonilimab monotherapy as neoadjuvant treatment in patients with MSI-H/dMMR colorectal cancer. Data presented at the 2024 ESMO Immuno-Oncology Congress showed a pathological complete response (pCR) rate of 84.6% and a major pathological response (MPR) rate of 100% among patients who proceeded to surgery, with a manageable safety profile.

As the first approved checkpoint bispecific antibody for cancer, cadonilimab has shown consistent clinical benefit across a broad range of patients, including both PD-L1-positive and PD-L1-negative individuals, in extensive real-world use and multiple Phase III trials. It is increasingly recognized as a foundational therapy in the immuno-oncology (IO) 2.0 era. Cadonilimab is currently being evaluated in 13 Phase III/registrational studies worldwide across major indications such as lung, gastric, cervical, liver and colon cancers, spanning first-line, second-line, perioperative, adjuvant and consolidation settings.

About Cadonilimab

Cadonilimab is a first-in-class PD-1/CTLA-4 bispecific antibody developed by Akeso for cancer immunotherapy. In June 2022, it received initial marketing approval from China's National Medical Products Administration (NMPA) for the treatment of patients with relapsed or metastatic cervical cancer who had progressed on or after platinum-based chemotherapy. In September 2024, cadonilimab was approved in combination with fluoropyrimidine- and platinum-based chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. In May 2025, cadonilimab plus platinum-based chemotherapy, with or without bevacizumab, was approved for the first-line treatment of persistent, recurrent, or metastatic cervical cancer.

By simultaneously targeting PD-1 and CTLA-4, cadonilimab delivers synergistic antitumor activity. It has shown robust efficacy with markedly lower toxicity and improved tolerability compared with conventional combination regimens, demonstrating potent activity across multiple tumor types independent of PD-L1 expression and offering breakthrough clinical value in immunotherapy-resistant and "cold" tumors.

To date, cadonilimab has been evaluated in more than 40 clinical studies spanning over 20 indications, including gastric, lung, liver, cervical, and pancreatic cancers. Thirteen Phase III/registrational studies are ongoing; three have met their primary endpoints; and two global Phase III/registrational trials are advancing.

About Akeso

Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, Akeso has built a comprehensive R&D innovation ecosystem anchored by its proprietary Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.

Backed by world-class GMP manufacturing facilities and a highly efficient, integrated commercialization system, Akeso has developed into a globally competitive biopharmaceutical enterprise. Leveraging its fully integrated, multi-functional platform, the Company maintains a robust pipeline of more than 50 innovative assets targeting cancer, autoimmune diseases, inflammation, metabolic disorders, and other major therapeutic areas. Of these, nearly 30 candidates have advanced into clinical trials, including 15 bispecific or multi-specific antibodies and bispecific ADCs. Eight innovative drugs are commercially available, and two additional drugs with three indications are currently under regulatory review for marketing approval.

Akeso is committed to becoming a global leader in biopharmaceuticals through efficient and breakthrough innovation in R&D, developing novel therapies that are first-in-class or best-in-class, and providing better disease solutions for patients around the world.

Forward-Looking Statements

This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the P.R. China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

Expanding horizons and inspiring growth through local youth engagement

MACAO, Oct. 9, 2026 /PRNewswire/ -- Sands China and NBA Cares jointly presented School Day today, the third event of the "NBA Cares x Sands Cares Community Impact Week" at Yuet Wah College, Macau. The event welcomed the return of NBA legend Mitch Richmond –– a 2002 NBA champion, six-time NBA All-Star, five-time All-NBA Team, and 2014 Basketball Hall of Fame Inductee –– to Macao, joining NBA coaches in visiting a local campus to engage with young Macao basketball players through a range of activities, including basketball skills training and cultural exchange experiences.

It was a valuable platform for teachers and students to gain insights from international basketball elites, while giving an NBA legend and coaches a firsthand look at the talent and potential of Macao's young athletes. The event underscores Sands China's long-standing commitment to the Macao community and its dedication to fostering a positive, inclusive and caring society. By bringing the impact of a premier international sporting event to the local community, the company aims to inspire positive youth development through this meaningful initiative.

School Day brought together around 600 participants, including Mitch Richmond and NBA coaches and management, alongside teachers and students from Yuet Wah College and Colégio Dom Bosco (Yuet Wah), senior management from Sands China, and the Sands Cares Ambassadors.

During the event, Mitch Richmond and NBA coaches led a dedicated basketball clinic for members of the boys' basketball teams from Yuet Wah College and Colégio Dom Bosco (Yuet Wah), who each won their division's championship in this year's Inter-School Basketball Competition in Macao. Through hands-on guidance and skills demonstrations, the basketball clinic provided precious learning opportunities for the students, inspiring and encouraging them in their pursuit of excellence.

Dr. Wilfred Wong, executive vice chairman of Sands China Ltd., said: "We would like to express our sincere gratitude to the Macao SAR government and various sectors of society for their long-standing support of our community initiatives, with special thanks to Yuet Wah College for arranging this initiative. These collective efforts provided a valuable opportunity for Macao's youth to learn from world-class sports elites. We are delighted to extend the impact of this international sporting event to a local school through School Day, leveraging the power of sports to nurture talent and foster cross-cultural exchange. This initiative not only provided young basketball players with an opportunity to enhance their basketball skills through close interactions with an NBA legend and coaches, but also inspired them to learn from the perseverance and pursuit of excellence that define world-class athletes. Today's event exemplifies Sands Cares' commitment to serving the community, fostering youth development, cultural exchange, and stronger social cohesion through meaningful engagement.

"Looking ahead, Sands China will continue to support the Macao SAR government's 'Tourism+' policy –– by drawing on international events in Macao to create more opportunities for the local community and younger generation to connect with the world and broaden their horizons, while showcasing Macao's unique appeal as a diverse and inclusive city on the global stage."

Ng Teng Kuong, principal of Yuet Wah College, said: "We are pleased to join hands with Sands China and NBA Cares to bring this meaningful campus activity to our students. The initiative provided members of our basketball team and fellow students with an invaluable opportunity to learn from an international basketball star, encouraging them to embrace a positive mindset both on and off the court. Through School Day, we brought the positive impact of an international sporting event into our school and the wider community, providing students with a unique opportunity to enhance their basketball skills, engage with world-class athletes, and expand their horizons. We sincerely thank Sands China and the NBA for their care and commitment to Macao's youth. Looking ahead, we will continue to strengthen collaboration with stakeholders across different sectors, creating more opportunities for students to engage with the wider world and unlock their full potential."

Beyond basketball exchange, the event featured meaningful cultural interactions. Students from Colégio Dom Bosco (Yuet Wah) delivered an electrifying freestyle rope-skipping performance on-site, showcasing the energy and diverse talents of Macao's youth. Accompanied by teachers and students at the school, NBA legend Mitch Richmond participated in a Chinese calligraphy session, learning firsthand the techniques of brushwork and ink application while gaining a deeper appreciation of the richness of Chinese culture. The experience fostered cultural exchange between East and West.

To further extend the positive impact, Sands China and the NBA donated basketballs and training equipment to Yuet Wah College, while establishing a new "Basketball Corner" on campus. Featuring a basketball-themed design, the space integrates areas for reading, social interaction and recreation, aiming to enrich students' campus life and extracurricular experiences while fostering a positive sporting culture.

School Day ended on a warm and cheerful note as students were presented with goodie bags assembled during the Impact Week's Tip-Off Day, conveying care and well wishes while encouraging them to pursue their dreams and challenge themselves to reach new heights.

Guests attending the School Day event included: Kathy Behrens, president of social responsibility and player programs of NBA; Wayne Chang, managing director of NBA Asia; NBA legend Mitch Richmond; Ng Teng Kuong, principal of Yuet Wah College; Iu Pek Fong, principal of Colégio Dom Bosco (Yuet Wah); Dr. Wilfred Wong, executive vice chairman of Sands China Ltd.; and Hubert Wang, chief operating officer of Sands China Ltd.

The "NBA Cares x Sands Cares Community Impact Week 2026" is taking place over five consecutive days, Oct. 7-11, featuring a diverse programme of activities focused on youth development, healthy living and community inclusion. Current NBA players and legends will engage with communities across Macao, with the initiative seeking to extend the impact of the NBA sporting event into the community and enable more Macao residents to experience the positive energy and excitement generated by the world-class basketball event.

The fourth event of Community Impact Week, Health and Wellness Day, will take place tomorrow (Oct. 10) at the Fuhong Society of Macau's Happy Kitchen Social Enterprise. During the event, an NBA legend, Sands China senior management, and Sands Cares Ambassadors will assemble and distribute boxed lunches to people in need in Macao, extending care and support to the local community.

"NBA Cares x Sands Cares Community Impact Week 2026" is part of Sands Cares, the global corporate citizenship programme of Sands China's parent company. As an important stakeholder in the Macao community, Sands China has actively fulfilled its corporate social responsibility for more than two decades. Through the programme, the company strives to connect with and serve the community, give back to society, and work alongside different sectors to build a more vibrant and inclusive Macao community.

For high resolution photos, please visit:

https://it-ezshare.sands.com.mo/exweb/share/0c0badbf-e2c9-4d1d-9f22-f5ec552cc24f

About Sands China Ltd.

Sands China Ltd. (Sands China or the Company) is incorporated in the Cayman Islands with limited liability and is listed on The Stock Exchange of Hong Kong Limited (HKEx: 1928). Sands China is the largest operator of integrated resorts in Macao. The Company's integrated resorts on the Cotai Strip comprise The Venetian^® Macao, The Plaza^® Macao, The Parisian^® Macao and The Londoner^® Macao. The Company also owns and operates Sands^® Macao on the Macao peninsula. The Company's portfolio features a diversified mix of leisure and business attractions and transportation operations, including large meeting and convention facilities; a wide range of restaurants; shopping malls; world-class entertainment at The Venetian Arena, The Londoner Arena, The Venetian Theatre, The Parisian Theatre, The Londoner Theatre and Sands Theatre; and a high-speed Cotai Water Jet ferry service between Hong Kong and Macao. The Company's Cotai Strip portfolio has the goal of contributing to Macao's transformation into a world centre of tourism and leisure. Sands China is a subsidiary of global resort developer Las Vegas Sands Corp. (NYSE: LVS).

For more information, please visit www.sandschina.com.

Sands Cares

A firm believer in the importance of corporate social responsibility, Sands China Ltd. engages with the local Macao community as a part of Sands Cares – the charitable giving programme of parent company Las Vegas Sands Corp. Sands Cares integrates the company's philanthropic work worldwide in four key areas: financial giving, community problem solving and collaboration, in-kind donations, and team member volunteerism.

Key areas of Sands Cares in Macao include the Sands Cares Ambassador programme for volunteering in the local community; charitable contributions to NGOs and community organisations; and sponsorship of community events.

For more information, please visit www.sands.com/sands-cares/.

About NBA Social Impact & Inclusion and NBA Cares

NBA Social Impact & Inclusion drives change on issues facing fans and communities by advancing needed resources and proven partners. We create data-driven strategies and programming to empower colleagues to bring their best self. NBA Cares works with NBA players and teams to highlight important issues through the NBA's digital, social and broadcast channels, live events and partnerships.

Media contacts:

Corporate Communications, Sands China Ltd.

Mabel Wu
Tel: +853 8118 2268
Email: [email protected]

Jesse Chiang
Tel: +853 8118 2054
Email: [email protected]

與青少年近距離互動交流 拓闊國際視野啟發成長

澳門2026年10月9日 /美通社/ -- 金沙中國攜手NBA關懷行動（NBA Cares）今日在澳門粵華中學舉行「NBA關懷行動 × 金沙關懷籃球公益周2026」第三日活動「校園日」，邀請NBA傳奇球星、2002年NBA總冠軍、六屆NBA全明星、五次入選All-NBA陣容，以及2014年入選籃球名人堂的米奇‧列治文（Mitch Richmond）再度來澳，聯同NBA教練走進校園，與本澳青年球員交流互動，共同投入籃球技術提升訓練及文化體驗等多元活動，為師生構建與國際籃球精英交流學習的寶貴平台，亦讓NBA球星親身感受澳門青年的體育實力；彰顯公司「金沙關懷」服務社區、推動正向及共融關愛的精神，致力將國際頂級體育盛事延伸至社區，啟迪青年正向成長。

活動當天匯聚NBA傳奇球星及教練、NBA管理層、澳門粵華中學及鮑思高粵華小學師生，以及金沙中國管理層及金沙中國關懷大使等約600人參與。期間，NBA球星米奇‧列治文及NBA教練為來自澳門粵華中學及鮑思高粵華小學、於本年度學界男子籃球決賽奪冠的成員進行籃球訓練營，透過親身指導及技術示範，為一眾青年學子帶來啟發與鼓舞。

金沙中國有限公司行政副主席王英偉博士表示：「衷心感謝澳門特區政府及社會各界對金沙中國社區工作的長期支持，並特別感謝澳門粵華中學協助籌辦是次活動，攜手為本澳青少年創造與國際級體育精英交流學習的寶貴機會。本次『校園日』將國際體育盛事延伸至澳門校園，進一步發揮體育育人及促進跨文化交流的作用。透過與NBA傳奇球星及教練近距離互動，本澳年輕球員不僅有機會精進球技，更能從世界級運動員身上學習堅毅拼搏、追求卓越的精神。是次活動體現了『金沙關懷』服務社區的精神，藉此互動互勉促進青少年發展、文化交流及社區連結。未來，金沙中國將持續支持澳門特區政府『旅遊+』施政方針，善用國際盛事落戶澳門的契機，為澳門社區及年青一代創造更多接軌世界、開拓視野的機會，並向世界展現澳門多元共融的城市魅力。」

澳門粵華中學校長吳庭廣表示：「本校十分高興能夠與金沙中國及NBA關懷行動合作，為學生帶來這次難得的校園活動。這活動讓本校的籃球隊員和學生有機會向國際級球星學習，鼓勵他們在球場內外都保持積極向上的態度。另外，這次活動成功將國際體育盛事的活力帶進社區和校園，學生在切磋球技之餘，又能與球星互相交流，對開闊他們的眼界有很大幫助。本校衷心感謝金沙中國和 NBA 團隊對本澳青少年的關心，未來我們會繼續與社會各界緊密合作，為同學創造更多接觸世界、發揮潛能的機會。」

此外，活動從體育交流延伸至文化互動，一眾鮑思高粵華小學的學生帶來精彩的花式跳繩表演，展現青春活力與多元才藝。而NBA傳奇球星米奇‧列治文則在學校師生陪同下體驗中國書法，從執筆、蘸墨到落筆，親身感受中華文化的獨特魅力，進一步促進中西文化交流與相互理解。

為延續活動帶來的正面影響，金沙中國與NBA特意向澳門粵華中學捐贈籃球及訓練器材，並於校內設立「籃球角」。該空間以籃球為主題，結合閱讀、交流及休憩功能，期望豐富學生的校園生活及課外體驗，並鼓勵青年培養正面的運動文化和團隊精神。

活動尾聲，一眾代表向在場學生送上於公益周啟動日悉心製作的愛心禮包，傳遞關懷與祝福，並勉勵他們勇敢追夢、持續挑戰自我。現場氣氛溫馨歡樂，為當天活動畫下圓滿句號。

出席「校園日」活動的嘉賓包括：NBA社會責任及球員項目總裁Kathy Behrens；NBA亞洲區董事總經理張文正；NBA傳奇球星米奇‧列治文（Mitch Richmond）；澳門粵華中學校長吳庭廣；鮑思高粵華小學校長余碧鳳；金沙中國有限公司行政副主席王英偉博士，以及首席營運總裁王志琪。

「NBA 關懷行動 × 金沙關懷籃球公益周」於10月7日至11日一連五日舉行，涵蓋青年發展、健康生活及社區共融等多元活動，邀請NBA現役及傳奇球星走進社區，與本澳廣泛社群交流互動，致力將NBA體育盛事的影響力延伸至社區，讓更多居民共享世界級籃球盛事帶來的正面影響。

明天（10月10日）將於澳門扶康會轄下社會企業「樂膳廚房」舉行公益周第四日活動「身心健康日」。屆時，NBA傳奇球星、金沙中國管理層及金沙關懷大使將聯同澳門扶康會學員，共同分裝及派發愛心午餐，為本澳有需人士送上關愛與支持。

「NBA關懷行動×金沙關懷籃球公益周」為母公司「金沙關懷」企業公民計劃的一部分。作為本澳社區的重要持份者，金沙中國二十多年來積極踐行企業社會責任，透過計劃連結社區、服務社群，回饋社會，與各界攜手共建更具活力及共融精神的澳門社區。

如欲下載相關高清圖片，請透過以下連結下載：

https://it-ezshare.sands.com.mo/exweb/share/0c0badbf-e2c9-4d1d-9f22-f5ec552cc24f

關於金沙中國有限公司

金沙中國有限公司（香港聯交所：1928，「金沙中國」或「公司」）是一所於開曼群島註冊成立的有限公司及在香港聯合交易所有限公司上市的公司。金沙中國是澳門最大的綜合度假村經營商，於路氹金光大道上設有澳門威尼斯人^®、澳門百利宮、澳門巴黎人^®，以及澳門倫敦人^® 等物業項目，同時擁有及經營位於澳門半島的澳門金沙。公司旗下的各綜合度假村集合多樣化的娛樂消閒、商務設施及客運業務，包括大型會議及展覽場地、各式餐廳食肆、購物中心、於威尼斯人綜藝館、倫敦人綜藝館、威尼斯人劇場、巴黎人劇場、倫敦人劇場及金沙劇場舉行的世界級娛樂表演，以及來往港澳的金光飛航高速渡輪服務。公司在路氹金光大道的各物業發展項目，堅定並持續地為建設澳門成為世界旅遊休閒中心貢獻力量。金沙中國是全球度假村發展商拉斯維加斯金沙集團股份有限公司（紐約證券交易所：LVS）的附屬公司。

如欲索取更多相關資訊，請瀏覽網頁https://hk.sandschina.com/index.html。

「金沙關懷」計劃

金沙中國有限公司不遺餘力推動及履行企業社會責任，積極參與母公司拉斯維加斯金沙集團所設立的「金沙關懷」企業公民計劃回饋澳門社區。「金沙關懷」計劃引領集團在全球各地開展慈善工作，包括經濟援助、社區援助及合作、物資捐贈及員工參與義工活動等。

「金沙關懷」企業公民計劃在澳門的主要項目包括：在澳門社區開展義務工作的金沙中國關懷大使計劃、向非牟利機構及社會企業捐款以及社區活動贊助等。

如欲索取更多相關資訊，請瀏覽網頁 https://www.sands.com/sands-cares/。 

關於NBA社會影響與包容度及NBA關懷

NBA社會影響與包容部門通過整合所需資源和可靠的合作夥伴，制定數據驅動的策略和項目，以應對球迷和社區面臨的問題，影響NBA生態系統，並賦能同事以最佳狀態投入工作，推動全球範圍內的成功。NBA關懷行動與NBA球員和球隊合作，通過NBA的數字、社交媒體和電視轉播渠道、現場活動及合作夥伴關係，聚焦重要社會議題。

傳媒查詢：

金沙中國有限公司 – 企業傳訊部

胡美寶                                                                
電話：+853 8118 2268                                      
電郵：     [email protected]                    

鄭文軒
電話：+853 8118 2054
電郵：[email protected]

GUANGZHOU, China, Oct. 9, 2026 /PRNewswire/ -- MINISO Group Holding Limited (NYSE: MNSO; HKEX: 9896) ("MINISO", "MINISO Group" or the "Company"), a world-leading IP-driven retailer and operation platform, today on a voluntary basis provided a business update on the latest performance of its flagship brand MINISO. The figures contained in this press release were based on the preliminary review of the Company's operational data.

Sales Performance of MINISO Chinese Mainland

Total GMV⁽¹⁾ of MINISO Chinese mainland for the three months ended September 30, 2026 ("26Q3") grew by 25%-30% year over year ("YoY"), accelerating from the first half of 2026, powered by a high-single-digit SSSG⁽¹⁾.

MINISO Chinese mainland maintained its strong momentum during the National Day holidays from October 1 to October 7, 2026, with total GMV growth of 20%-25% YoY, powered by a low-single-digit SSSG.

Sales Milestone of Proprietary IP YOYO

YOYO, MINISO's flagship proprietary IP, has generated GMV of over RMB1 billion for the first nine months of 2026 and has officially entered the global IP "One Billion Club". Since its first product launch in June 2025, YOYO has expanded into 53 countries and regions worldwide, emerging as one of the fastest Chinese original IPs to achieve large-scale global expansion. Mr. Guofu Ye, Founder, Chairman and CEO of MINISO, stated that YOYO has validated MINISO's strategic capability as a "world's leading IP operation platform", and that MINISO will empower more Chinese original IPs to scale up and accelerate in the global market.

Sales Performance of MINISO Overseas Markets

MINISO overseas markets' performance was largely in line with the Company's guidance. MINISO USA delivered a GMV growth of around 20% YoY in 26Q3. Notably, it rebounded to over 30% GMV YoY growth and positive SSSG in September 2026 bolstered by new product arrivals.

This press release was announced by the Company on a voluntary basis to inform shareholders and potential investors of the Company of the latest business update of the Company. This press release was based on the Board's preliminary review of the relevant operational data of the Company and the information currently available to the Board, and it was not based on any figures or information which have been audited or reviewed by the Company's auditors. The information contained in this press release may be subject to change and adjustment. Shareholders and potential investors of the Company should note that sales performance of IP products is subject to seasonality, marketing cycles, and the timing of new product launches and that operational data during the National Day holiday period represents a short-term snapshot and is not necessarily indicative of the Company's performance for the entire fourth quarter of 2026 or any future period. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Company's securities.

About MINISO Group

MINISO Group is a world-leading IP-driven retailer and operation platform offering immersive consumption experiences powered by value-for-money and aesthetic products featuring IP designs. Founded in 2013, the Company has established two brands, MINISO and TOP TOY. MINISO Group has built a worldwide IP ecosystem through its top licensed IPs and proprietary IPs dual-engine model. Guided by its "Life is for Fun" philosophy, it delivers engaging experiences and emotional value to consumers around the world. For more information, please visit https://ir.miniso.com/.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "may", "will", "expect", "anticipate", "aim", "estimate", "intend", "plan", "believe", "is/are likely to", "potential", "continue" or other similar expressions. Among other things, the quotations from management in this announcement, as well as MINISO's strategic and operational plans, contain forward-looking statements. MINISO may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC") and The Stock Exchange of Hong Kong Limited (the "HKEX"), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about MINISO's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: MINISO's mission, goals and strategies; future business development, financial conditions and results of operations; the expected growth of the retail market and the market of branded variety retail of lifestyle products in China and globally; expectations regarding demand for and market acceptance of MINISO's products; expectations regarding MINISO's relationships with consumers, suppliers, Retail Partners, local distributors, and other business partners; competition in the industry; proposed use of proceeds; and relevant government policies and regulations relating to MINISO's business and the industry. Further information regarding these and other risks is included in MINISO's filings with the SEC and the HKEX. All information provided in this press release and in the attachments is as of the date of this press release, and MINISO undertakes no obligation to update any forward-looking statement, except as required under applicable law.

Note: 
(1) For definitions of the operating and financial metrics used in this press release, please refer to the Company's financial results announcements and annual reports.

Investor Relations Contact

MINISO Group Holding Limited
Email: [email protected]
Phone: +86 (20) 36228788 Ext.8039

This morning (9th), the HSI opened 155 pts higher. With the upswing sharpening in the afternoon session, the index closed near the day's peak at 24,211, up 425 pts or 1.79%. Main board turnover reached HKD209.199 billion. The HSCEI closed at 8,147, up 137.29 pts or 1.71%. The HSTECH closed at 4,197, up 124 pts or 3.06%.

Techs were the key drivers of the rally. TENCENT (00700.HK) closed up 3.26%; MEITUAN-W (03690.HK) spiked 3.03%; NTES (09999.HK) swelled 3.75%; BABA-W (09988.HK) rallied 2.59% after Jefferies raised its TP to HKD186; BIDU-W (09888.HK) climbed 1.04%; and KUAISHOU-W (01024.HK) advanced 5.47%.

Automakers outshone, with XIAOMI-W (01810.HK) becoming the best-performing blue chip of the day as its share price surged 9.72%. Orders locked in for SkyNomad exceeded 70,000 units within 30 days of launch. LI AUTO-W (02015.HK), BYD COMPANY (01211.HK) and GEELY AUTO (00175.HK) all mounted more than 3%. Battery giant CATL (03750.HK) closed up 3.06% after its total battery patent holdings over the past decade ranked first globally, marking the first time a Chinese company topped the list.

Among blue chips, HSBC HOLDINGS (00005.HK) rebounded 1.82%; AIA (01299.HK) soared 2.89%; LENOVO GROUP (00992.HK) recovered 1.61%; while CHINA LIFE (02628.HK) and CSPC PHARMA (01093.HK) each dived more than 2%. Goldman Sachs expected Macau's gaming EBITDA to rebound 5% QoQ in 3Q26 and favored SANDS CHINA LTD (01928.HK) and GALAXY ENT (00027.HK) to Outperform. The two stocks rallied 3.99% and 4.83% respectively. Consumers and caterers also attracted buying interest, with MENGNIU DAIRY (02319.HK), HAIDILAO (06862.HK) and LI NING (02331.HK) all up more than 3%.
~

AASTOCKS Financial News
Website: www.aastocks.com

Australian AI data center operator Firmus, backed by NVIDIA Corporation (NVDA.US), announced that it has withdrawn its Australia listing plan due to market volatility.

Firmus plans to raise USD2-3 billion through private financing and is in talks with existing investors, Bloomberg reported, citing sources.

Sources added that Firmus will explore the possibility of listing in the US in the long run.
~

AASTOCKS Financial News
Website: www.aastocks.com

• 前莫德納腫瘤轉化醫學負責人Lakshmi Srinivasan博士、前莫德納腫瘤疫苗研究及早期臨床轉化負責人Brandon Coder博士加盟雲頂新耀
• 兩位科學家的加入將進一步助力雲頂新耀mRNA產品管線的全球臨床開發，包括計劃於2026年第四季度啟動個性化腫瘤治療性疫苗EVM16 Ib期研究者發起的臨床試驗（IIT）、於2027年初在美國遞交新藥臨床試驗申請（IND），以及預計於2027年第一季度完成通用型腫瘤治療性疫苗EVM14 I期臨床研究

上海2026年10月9日 /美通社/ -- 雲頂新耀（HKEX 1952.HK）是一家專注於創新藥研發、臨床開發、製造及商業化的生物製藥公司，今日宣佈任命Lakshmi Srinivasan博士擔任高級副總裁、轉化醫學負責人，Brandon Coder博士擔任轉化科學與早期研究副總裁。此次任命將進一步強化雲頂新耀mRNA技術平台的全球研發能力與國際合作佈局。未來，公司將持續匯聚國際化頂尖人才，整合研發資源，加速全球創新戰略落地。

兩位新任高管均擁有深厚的行業經驗和專業背景，此前曾在莫德納等全球領先的生物製藥企業負責腫瘤疫苗研發，具備從早期發現到臨床轉化及臨床開發的完整實戰經驗。兩位資深科學家將在雲頂新耀管理層的領導下，圍繞公司全球mRNA的研發戰略，重點推動mRNA技術平台在美國的臨床開發及相關業務佈局，並與中國研發團隊密切協作，進一步賦能mRNA技術平台的進化。

雲頂新耀董事會主席吳以芳表示：「我們非常高興Srinivasan博士和Coder博士加入雲頂新耀。兩位資深科學家在腫瘤疫苗研發、轉化醫學及臨床開發領域擁有深厚經驗，將進一步強化公司的全球mRNA研發能力，助力推進自主mRNA技術平台及相關產品管線的全球臨床開發。此次任命體現了雲頂新耀持續匯聚全球頂尖人才、推進全球mRNA戰略的承諾。」

Lakshmi Srinivasan博士

Srinivasan博士擁有20年腫瘤免疫領域研發經驗，作為資深免疫學家，她長期致力於推動創新腫瘤免疫療法從早期發現研究走向臨床開發，在腫瘤疫苗、mRNA-LNP（脂質納米顆粒）技術、T細胞療法及轉化醫學開發等領域擁有豐富經驗，研發經驗覆蓋從臨床前研究到臨床概念驗證的多個階段。

加入雲頂新耀前，Srinivasan博士於2023年至2025年就職於莫德納（Moderna Therapeutics），曾任執行總監、腫瘤轉化醫學負責人；此前她曾任Repertoire Immune Medicines副總裁、臨床前科學與轉化醫學負責人，Neon Therapeutics（後併入BioNTech）轉化科學高級總監及賽諾菲（Sanofi）腫瘤藥物發現負責人。

Srinivasan博士長期從事個性化新抗原疫苗臨床轉化研究，並在該領域發表多篇高影響力學術論文。她作為通訊作者參與了NEO-PV-01的Ib期臨床研究，相關研究成果分別發表於《Cell》（2020年）^[1]和《Cancer Cell》（2022年）^[2]。此外，她也作為共同作者參與了莫德納 intismeran autogene（mRNA-4157/V940）的多篇代表性論文，包括發表於《Cancer Discovery》（2024年）的I期KEYNOTE-603研究中mRNA-4157/V940單藥及聯合帕博利珠單抗治療所誘導的T細胞應答^[3]；以及發表於《JCO Oncology Advances》（2026年）的mRNA-4157/V940聯合帕博利珠單抗治療切除後黑色素瘤的隨機IIb期 KEYNOTE-942研究3年隨訪結果^[4]。

Srinivasan博士曾在哈佛醫學院（Harvard Medical School）免疫疾病研究所（Immune Disease Institute）開展博士後研究，擁有印度科學研究院（Indian Institute of Science）微生物學與細胞生物學博士學位、賈瓦哈拉爾‧尼赫魯大學（Jawaharlal Nehru University）生物技術碩士學位及德裡大學（University of Delhi）生物化學學士學位。

Brandon Coder博士

Coder博士擁有超過11年的生物醫藥行業研發經驗，長期致力於推動T細胞免疫療法從早期發現研究走向IND申報及早期臨床概念驗證。他在腫瘤疫苗、mRNA/LNP平台技術及in vivo CAR療法領域擁有豐富經驗。

加入雲頂新耀前，Coder博士於2019年至2025年就職於莫德納，曾擔任莫德納腫瘤疫苗研究副科學總監等職務。在職期間，他曾是mRNA-4157/V940研究及全球藥理學負責人，並作為共同作者參與該項目KEYNOTE-603 I期臨床研究，相關研究成果發表於《Cancer Discovery》（2024年）^[3]。此外，他同時是莫德納共享抗原腫瘤疫苗mRNA-4359和mRNA-4106共享抗原發現及疫苗設計框架的共同發明人，並負責相關研發工作。

此前，Coder博士還曾任Advaxis Immunotherapies腫瘤免疫研發副總監，負責個性化及現貨型腫瘤疫苗的研發。

Coder博士擁有美國北德克薩斯大學健康科學中心（University of North Texas Health Science Center）生物醫學科學博士學位，研究方向為免疫學與遺傳學，並擁有德州理工大學（Texas Tech University）生物學學士學位。

關於雲頂新耀mRNA技術平台

作為全球少數擁有全流程、自主可控mRNA技術平台的生物製藥公司之一，雲頂新耀已構建起涵蓋抗原設計、mRNA序列優化、脂質納米顆粒（LNP）靶向遞送技術到產業化生產的完整產業鏈平台，擁有mRNA平台價值鏈端到端的能力，並成功實現臨床驗證。

雲頂新耀依托業內領先且完全整合的AI+mRNA平台，不僅可實現規模化生產，還擁有強大的知識產權組合。公司已建立並持續優化自主的LNP遞送技術平台，已在可電離脂質與隱形脂質方向形成專利群，擁有超過600種內部專有脂質分子，滿足多類型項目需求。通過自研的第三代AI算法的加持，顯著提升了mRNA的表達水平，為mRNA腫瘤疫苗的開發奠定了堅實基礎。

基於自主知識產權的AI+mRNA平台，雲頂新耀正多路徑推進mRNA腫瘤治療性疫苗和自體生成CAR-T平台，治療腫瘤及自身免疫疾病：

• 個性化腫瘤治療性疫苗EVM16完成首次人體臨床數據讀出，顯示出良好的安全性、耐受性、顯著的免疫原性及積極的初步療效信號，部分數據已於2026年美國癌症研究協會（AACR）年會上公佈。EVM16計劃於2026年第四季度啟動IIT（研究者發起的臨床試驗） Ib期臨床研究，並在Ia研究基礎上，開展新的適應症擴展隊列，進行有效性探索；並計劃於2027 H1遞交美國食品藥品監督管理局（FDA）新藥臨床試驗申請（IND）。
• 通用現貨型腫瘤相關抗原（TAA）疫苗EVM14，繼2025年相繼獲得美國FDA及中國國家藥品監督管理局「雙重IND」批准後，公司將於2027年第一季度完成臨床I期單藥劑量遞增。
• 自體生成CAR-T療法EVM18已啟動針對自身免疫疾病的IIT研究，同時公司正穩步推進其全球IND申報工作。

參考文獻

1. Ott PA, et al., A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Cell, 2020
2. Awad MA, et al., Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. Cancer Cell, 2022
3. Gainor et al., T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study. Cancer Discovery, 2024
4. Carlino et al., Three-Year Update of a Randomized Phase IIb Study of the Individualized Neoantigen Therapy Intismeran Autogene (mRNA-4157, V940) Plus Pembrolizumab Versus Pembrolizumab in Resected Melanoma. JCO advances, 2026

關於雲頂新耀
雲頂新耀是一家專注於創新藥研發、臨床開發、製造和商業化的生物製藥公司，致力於滿足全球市場尚未滿足的醫療需求。雲頂新耀的管理團隊在中國及全球領先製藥企業擁有深厚的專長和豐富的經驗。公司在浙江嘉善擁有具備商業化規模的全球生產基地，並依據中國、歐盟和WHO標準建立了完善的GMP生產質量管理體系。

公司聚焦自身免疫、眼科、急重症及CKM（心血管、腎臟及代謝）等疾病治療領域，已打造集全渠道商業化體系與藥品全生命週期商業化能力於一體的商業化平台，並以擁有全球權益的自研mRNA平台為基礎，持續推進mRNA in vivo CAR-T與mRNA腫瘤疫苗等現有管線，同時通過引進及生態孵化潛力平台，拓展研發能力，同時強化全球化佈局，加快國際化發展進程。更多信息，請訪問公司官網：www.everestmedicines.com。

前瞻性聲明
本新聞稿所發佈的信息中可能會包含某些前瞻性表述，乃基於本公司或管理層在做出表述時對公司業務運營情況及財務狀況的現有看法、相信、和現有預期，可能會使用「將」、「預期」、「預測」、「期望」、「打算」、「計劃」、「相信」、「預估」、「確信」及其他類似詞語進行表述。這些前瞻性表述並非對未來業績的保證，會受到風險、不確定性及其他因素的影響，有些乃超出本公司的控制範圍，難以預計。因此，受我們的業務、競爭環境、政治、經濟、法律和社會情況的未來變化及發展等各種因素及假設的影響，實際結果可能會與前瞻性表述所含資料有較大差別。本公司及各附屬公司、各位董事、管理人員、顧問及代理未曾且概不承擔更新該稿件所載前瞻性表述以反映在本新聞稿發佈日後最新信息、未來項目或情形的任何義務，除非法律要求。

• Lakshmi Srinivasan, PhD, former Executive Director and Head of Oncology Translational Medicine at Moderna, and Brandon Coder, PhD, former Research & Early Translational Lead, Cancer Vaccines at Moderna, join Everest Medicines
• Appointments support continued advancement of Everest's mRNA pipeline, including a planned Phase 1b investigator-initiated trial of EVM16 in Q4 2026, U.S. IND submission in early 2027, and EVM14 Phase 1 study completion in Q1 2027

SHANGHAI, Oct. 9, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced the appointments of Lakshmi Srinivasan, PhD, as Senior Vice President, Head of Translational Medicine, and Brandon Coder, PhD, as Vice President, Translational Sciences & Discovery. The appointments further strengthen the Company's global R&D capabilities in mRNA therapeutics, and support the continued advancement of its proprietary mRNA platform and pipeline. The Company will continue to invest in world-class talent to accelerate the development of its mRNA programs and to realize the platform's potential for global innovation.

Both executives are seasoned scientists in mRNA cancer vaccines, with deep experience spanning early discovery through clinical development and leadership roles in oncology vaccine research at Moderna and other leading biopharmaceutical companies. At Everest, they will drive clinical development of the Company's mRNA programs and expand Everest's presence in the United States, in line with the Company's global mRNA R&D strategy, while working closely with the China R&D team.

"We are very pleased to welcome Dr. Srinivasan and Dr. Coder to Everest as we continue to strengthen our global mRNA R&D capabilities," said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. "Their deep experience in cancer vaccine research, translational medicine, and clinical development will be highly valuable as we advance our proprietary mRNA platform and broader pipeline. Their appointments reflect our continued commitment to investing in world-class talent and advancing our global mRNA strategy."

Lakshmi Srinivasan, PhD

Dr. Srinivasan is a seasoned immunologist with 20 years of experience advancing innovative immuno-oncology therapeutics from discovery through clinical development. Her expertise spans cancer vaccines, mRNA-LNP technologies, T-cell therapies, and translational development from preclinical research through clinical proof of concept.

Prior to joining Everest Medicines, Dr. Srinivasan served as Executive Director and Head of Oncology Translational Medicine at Moderna Therapeutics from 2023 to 2025. She previously held leadership roles at Repertoire Immune Medicines, Neon Therapeutics (later acquired by BioNTech), and Sanofi Oncology.

Dr. Srinivasan has played a key role in the clinical translation of personalized neoantigen vaccines and has authored multiple high-profile publications in the field. She served as corresponding author on Phase 1b studies of NEO-PV-01 published in Cell (2020)^[1] and Cancer Cell (2022),^[2] and co-authored publications on Moderna's intismeran autogene (mRNA-4157/V940), including the Phase 1 KEYNOTE-603 study published in Cancer Discovery (2024)^[3]  and the three-year follow-up of the randomized Phase 2b KEYNOTE-942 study published in JCO Oncology Advances (2026).^[4] 

Dr. Srinivasan conducted postdoctoral research at the Immune Disease Institute at Harvard Medical School. She holds a PhD in Microbiology and Cell Biology from the Indian Institute of Science, a master's degree in biotechnology from Jawaharlal Nehru University, and a bachelor's degree in biochemistry from Delhi University.

Brandon Coder, PhD

Dr. Coder brings more than 11 years of industry experience advancing T cell immunotherapies from discovery through investigational new drug (IND) submissions and early clinical proof of concept, with expertise in cancer vaccines, mRNA/LNP platform technology, and in vivo CAR therapies.

Prior to joining Everest Medicines, Dr. Coder held scientific roles at Moderna from 2019 to 2025, most recently as Associate Scientific Director of Cancer Vaccine Research. He served as research and global pharmacology lead for intismeran autogene (mRNA-4157/V940), where he co-authored the Phase 1 KEYNOTE-603 study of mRNA-4157/V940 published in Cancer Discovery (2024).^[3]  He also co-invented and led development of the shared-antigen discovery and vaccine design framework for mRNA-4359 and mRNA-4106.

Previously, Dr. Coder served as Associate Director of Immuno-Oncology Research at Advaxis Immunotherapies, where he developed personalized and off-the-shelf cancer vaccines. He holds a PhD in Biomedical Sciences, with a focus on immunology and genetics, from the University of North Texas Health Science Center and a bachelor's degree in biology from Texas Tech University.

About Everest's mRNAPlatform

Everest has built an industry-leading and fully integrated AI+mRNA platform that accelerates mRNA product development.

As one of the few global biopharmaceutical companies with a fully integrated and proprietary mRNA platform, Everest has built end-to-end capabilities across the entire value chain, covering antigen design, sequence optimization, LNP delivery, and scalable manufacturing. Everest has established and optimized its proprietary LNP delivery system, with patent coverage including ionizable lipids and stealth lipids. The internal lipid library (>600 lipids) supports multiple programs, including vaccines and in vivo CAR-T therapies. Backed by third-generation AI algorithms, Everest's AI+mRNA platform significantly boosts expression and immunogenicity, laying a solid foundation for mRNA-based cancer vaccine development.

Leveraging its proprietary AI+mRNA platform, Everest is advancing multiple mRNA therapeutic vaccine and in vivo CAR-T programs across oncology and autoimmune diseases.

• EVM16, a personalized mRNA therapeutic cancer vaccine, has completed its first-in-human clinical data readout, demonstrating a favorable safety and tolerability profile, robust immunogenicity, and promising preliminary efficacy. Selected data were presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. Following the Phase 1a study, a Phase 1b investigator-initiated trial (IIT) of EVM16 is planned in Q4 2026, with new indication expansion cohorts expected to further explore efficacy. The Company plans to submit an IND application to the U.S. Food and Drug Administration (FDA) in the first half of 2027.
• EVM14, an off-the-shelf tumor-associated antigen (TAA) mRNA cancer vaccine, received IND clearance from the U.S. FDA and IND approval from China's National Medical Products Administration (NMPA) in 2025. The Phase 1 monotherapy dose-escalation study is expected to be completed in Q1 2027.
• EVM18, an in vivo CAR-T therapy, is being evaluated in an IIT in autoimmune diseases, with global IND filing underway.

Reference

1. Ott PA, et al., A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Cell, 2020
2. Awad MA, et al., Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. Cancer Cell, 2022
3. Gainor et al., T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study. Cancer Discovery, 2024
4. Carlino et al., Three-Year Update of a Randomized Phase IIb Study of the Individualized Neoantigen Therapy Intismeran Autogene (mRNA-4157, V940) Plus Pembrolizumab Versus Pembrolizumab in Resected Melanoma. JCO Oncology advances, 2026

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies.

The Company's therapeutic areas of focus include autoimmune, ophthalmology, critical care, and CKM (cardiovascular, kidney, and metabolic) diseases. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company's website: www.everestmedicines.com.

Forward-Looking Statements

This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates,""confident" and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.

Meta Platforms, Inc. (META.US) has banned ByteDance, the former controlling shareholder of TikTok, from placing advertisements and paid promotional messages on its platforms. The restrictions will take effect in the US, Canada, Egypt, Indonesia, Japan, Thailand and Vietnam, and will also apply to third-party advertisers in the above countries directing traffic to TikTok and other ByteDance products.

Meta spokesperson Chris Sgro said in a statement that the company sees no need to carry advertisements from competitors whose objective is to divert users away from Meta's applications. He added that refusing to provide promotional services to competitors is a normal business practice across industries, and the company will continue to compete through product quality and user experience.
~

AASTOCKS Financial News
Website: www.aastocks.com

Current Mavericks and Rockets players and NBA legends join together
 to engage with Macao youth and inspire positive growth

MACAO, Oct. 9, 2026 /PRNewswire/ -- Ahead of The NBA China Games 2026, Sands China and NBA Cares held the Tip-OffDay as part of the "NBA Cares x Sands Cares Community Impact Week 2026" on Oct. 8 at The Venetian Arena. Embodying a shared spirit of care for the community, the event brought together around 400 participants, including current players from the Dallas Mavericks and the Houston Rockets; NBA executives, legends and coaches; executives and team members from Las Vegas Sands and Sands China, members of local school basketball teams, and local and international media. Together, they extended the impact of world-class basketball event beyond the court and into the community. Through personal sharing by NBA players, a basketball clinic, and goodie bag packing, the event brought energy, care and warmth to different sectors of the Macao community.

During the event, the Mavericks and Rockets players took on the role of youth mentors, engaging with students from two championship teams of the Macao Inter-School Basketball Competition: the Girls D Division team of Keang Peng School and Boys D Division team of Colégio dom Bosco (Yuet Wah). The NBA players also shared with local students the journeys of pursuing their dreams and experiences from their professional basketball careers, inspiring local students through the perseverance, determination and relentless dedication that underpin the success of elite athletes. Players and coaches from both NBA teams then led local students in a basketball clinic on the NBA court at The Venetian Arena, providing skills demonstrations and hands-on coaching in practical techniques.

Throughout the clinic, players engaged closely with the students, instilling the values of sportsmanship and teamwork. The event also offered Macao youth a valuable opportunity to learn directly from world-class basketball professionals, enhancing their basketball skills, broadening their horizons and inspiring them to pursue their aspirations and strive for excellence.

The Tip-Off event was also attended by two NBA legends: Yao Ming, eight-time NBA All-Star, five-time All-NBA Team, and 2016 Basketball Hall of Fame Inductee, as well as chairman of the Yao Foundation, and Shawn Marion, 2011 NBA champion, four-time NBA All-Star and two-time All-NBA Team. Both legends engaged with participants on-site, bringing further care and inspiration to the Impact Week.

Patrick Dumont, chairman of the board and chief executive officer of Las Vegas Sands Corp., and chairman of the board and non-executive director of Sands China Ltd., and governor of the Dallas Mavericks, said: "For more than two decades, we have grown alongside Macao and remained steadfast in our confidence in the city. For us, the value of major international sporting events extends well beyond what takes place inside the arena. Their lasting significance lies in their ability to contribute to social progress and the development of the city. Last year, we brought The NBA China Games back to Macao, adding to the city's growing portfolio of internationally renowned sporting events, while harnessing the power of sport to bring communities together, inspire young people and foster international exchange. This year, we are once again bringing together Sands Cares and NBA Cares to extend the impact of this major sporting event into the Macao community, enabling people of different ages, backgrounds and sectors to experience the spirit and positive energy of the NBA.

"We sincerely thank the Central People's Government, the Macao SAR Government and all sectors of the community for their longstanding support, which enables us to continue extending the benefits of major events throughout the community. Looking ahead, we will continue to leverage the international network of Las Vegas Sands and Sands China's integrated resort platform and pursue innovative, forward-looking approaches to further deepening the cross-sector 'Tourism+' development, supporting the development of a harmonious and inclusive community in Macao, and injecting continued momentum into Macao's position as a World Centre of Tourism and Leisure."

Adam Silver, commissioner of the NBA, said: "I want to particularly thank Patrick Dumont and Sands China for all they have done to make this event possible and the NBA players and teams for making this trip and being here. This means a lot to all of us and so much to the Macao community. There is no substitute for experiencing Macao in person. And to all the boys and girls here today, this event is really about you. Wherever the NBA goes around the world, we want to create opportunities for young people who love the game. Basketball teaches teamwork, respect and discipline, and these are lessons that can help you achieve whatever goals you set for yourselves in life, not just in basketball. My message to all of you is to dream big. That's what so many great NBA players did. They had a dream and pursued it. So take advantage of the opportunity to learn from the inspiring people around you today, and use the lessons you gain through sports to pursue your own dreams."

Patrick Fertitta, vice chairman of the Houston Rockets and Comets, said: "On behalf of the Houston Rockets, I would like to express our sincere appreciation to Adam Silver, Patrick Dumont along with Sands China, as well as all our partners for making this meaningful week possible. We are delighted to join the Mavericks and the wider NBA community in Macao, not only to celebrate the game of basketball, but also to demonstrate how sport can inspire young people and create a positive impact in the community. We are especially honoured to have Hall of Famer Yao Ming with us today. His remarkable legacy extends far beyond the game, and his influence continues to bring people together across cultures and generations. To the young people here today, I encourage you to dream big, work hard and believe in yourselves. Basketball teaches us the values of teamwork, perseverance and giving back to others. I hope these are lessons you will carry with you, both on and off the court, as you pursue your aspirations and contribute positively to your communities."

In addition, NBA players joined local students, executives from Las Vegas Sands and Sands China, and Sands Cares Ambassadors in assembling goodie bags to share care and warm wishes with the community. The bags contained towels, notebooks, commemorative water bottles provided by the Dallas Mavericks, sports wristbands from the Houston Rockets, G Bear blind boxes and other gifts. Some of the care packages were presented to the students on-site, while the remainder will be distributed to people in need within the community during subsequent Impact Week activities, extending the spirit of care to more members of the local community.

Following the Tip-Off event, the Dallas Mavericks and the Houston Rockets each held pre-game training sessions at The Venetian Arena, making final preparations for their first matchup the following day (Oct. 9). The two NBA teams fine-tuned their tactics as they prepared to take to the court at their best.

Guests attending the Tip-Off event included: Adam Silver, commissioner of the NBA; Mark Tatum, deputy commissioner and chief operating officer of the NBA; Michael Ma, CEO of NBA Asia Pacific; Wayne Chang, managing director of NBA Asia; Kathy Behrens, president of social responsibility and player programs of NBA; NBA legends Shawn Marion and Yao Ming; Dr. Miriam Adelson, co-founder of Las Vegas Sands Corp.; Patrick Dumont, chairman of the board and chief executive officer of Las Vegas Sands Corp., and chairman of the board and non-executive director of Sands China Ltd., and governor of the Dallas Mavericks; Dr. Wilfred Wong, executive vice chairman of Sands China Ltd.; Grant Chum, chief executive officer and executive director of Sands China Ltd.; Hubert Wang, chief operating officer of Sands China Ltd.; Dave Sun, executive vice president and chief financial officer of Sands China Ltd. and managing director of Venetian Macau Limited.

The "NBA Cares x Sands Cares Community Impact Week 2026" is taking place over five consecutive days, Oct. 7-11, featuring a diverse programme of activities focused on youth development, healthy living and community inclusion. Current NBA players and legends will engage with communities across Macao, with the initiative seeking to extend the impact of the NBA sporting event into the community and enable more Macao residents to experience the positive energy and excitement generated by the world-class basketball event.

The Impact Week continues on Oct. 9 with "School Day" at Yuet Wah College in Macao. NBA legends and coaches will visit the school to engage directly with local students through basketball training and interactive exchanges, helping young participants enhance their basketball skills and inspiring greater enthusiasm for sport.

"NBA Cares x Sands Cares Community Impact Week 2026" is part of Sands Cares, the global corporate citizenship programme of Sands China's parent company. As an important stakeholder in the Macao community, Sands China has actively fulfilled its corporate social responsibility for more than two decades. Through the programme, the company strives to connect with and serve the community, give back to society, and work alongside different sectors to build a more vibrant and inclusive Macao community.

About Sands China Ltd.

Sands China Ltd. (Sands China or the Company) is incorporated in the Cayman Islands with limited liability and is listed on The Stock Exchange of Hong Kong Limited (HKEx: 1928). Sands China is the largest operator of integrated resorts in Macao. The Company's integrated resorts on the Cotai Strip comprise The Venetian^® Macao, The Plaza^® Macao, The Parisian^® Macao and The Londoner^® Macao. The Company also owns and operates Sands^® Macao on the Macao peninsula. The Company's portfolio features a diversified mix of leisure and business attractions and transportation operations, including large meeting and convention facilities; a wide range of restaurants; shopping malls; world-class entertainment at The Venetian Arena, The Londoner Arena, The Venetian Theatre, The Parisian Theatre, The Londoner Theatre and Sands Theatre; and a high-speed Cotai Water Jet ferry service between Hong Kong and Macao. The Company's Cotai Strip portfolio has the goal of contributing to Macao's transformation into a world centre of tourism and leisure. Sands China is a subsidiary of global resort developer Las Vegas Sands Corp. (NYSE: LVS).

For more information, please visit www.sandschina.com.

Sands Cares

A firm believer in the importance of corporate social responsibility, Sands China Ltd. engages with the local Macao community as a part of Sands Cares – the charitable giving programme of parent company Las Vegas Sands Corp. Sands Cares integrates the company's philanthropic work worldwide in four key areas: financial giving, community problem solving and collaboration, in-kind donations, and team member volunteerism.

Key areas of Sands Cares in Macao include the Sands Cares Ambassador programme for volunteering in the local community; charitable contributions to NGOs and community organisations; and sponsorship of community events.

For more information, please visit www.sands.com/sands-cares/ 

About NBA Social Impact & Inclusion and NBA Cares

NBA Social Impact & Inclusion drives change on issues facing fans and communities by advancing needed resources and proven partners. We create data-driven strategies and programming to empower colleagues to bring their best self. NBA Cares works with NBA players and teams to highlight important issues through the NBA's digital, social and broadcast channels, live events and partnerships.

Media contacts:

Corporate Communications, Sands China Ltd.
Mabel Wu
Tel: +853 8118 2268
Email: [email protected]

Jesse Chiang
Tel: +853 8118 2054
Email: [email protected]